All News
RheumNow Podcast – Tofacitinib Safety Concerns (2.5.2021)
Dr. Jack Cush reviews and discusses the news and journal reports from the past week on RheumNow.com.
Read ArticleLinks:
Links:
Links:
JAK Inhibitor Misses Endpoint in Safety Study. Now What?
Pfizer announced results Wednesday from its FDA-mandated postmarketing safety study of tofacitinib (Xeljanz), and they don't bode well for the drug and possibly others in its class.
Read ArticleLinks:
Links:
Links:
Dr. John Cush RheumNow ( View Tweet)
Low Risk of TB with Secukinumab
JAMA Dermatology has reported on a longitudinal cohort study of 12,319 secukinumab (SEC) treated patients (psoriasis, psoriatic arthritis, or ankylosing spondylitis); no new cases of active tuberculosis (TB) and very few cases of latent tuberculosis infection (LTBI) were f
Read ArticleLinks:
Links:
Links:
Links:
Dr. John Cush RheumNow ( View Tweet)
2020 Rheumatology Year in Review
2020 was historic, memorable and game-changing. Under the cloud of COVID-19, there were many significant and memorable advances and setbacks for the rheumatology world. In our accounting of most read articles for 2020, (not surprisingly) 17/20 were COVID-related.
Read ArticleLinks:
Delays in Diagnosis of Axial Spondyloarthritis
The diagnosis of axial spondyloarthritis (and anklylosing spondylitis) (axSpA) is often delayed and usually not diagnosed by rheumatologists; a recent metanalysis shows that longer delays were attributable to lower education levels, younger age at onset and absence of extra-articular manifes
Read ArticleCorticosteroid Use Hikes CV Risks in Rheumatic Patients
UK Clinical Practice Research Datalink population study shows that patients with immune-mediated inflammatory diseases, such as RA, PMR, GCA and IBD, have an augmented risk of CV outcomes with glucocorticoid use; even lower doses had a near doubling of their underlying CVD risk.
Read ArticleLinks:
Dr. John Cush RheumNow ( View Tweet)
Links:
EULAR Guidance on Patient Adherence to Meds
Non-adherence may be the single most untold risk to suboptimal outcomes in the care of musculoskeletal disease. It has been estimated that 30-80% of patients with rheumatic and musculoskeletal diseases (RMDs) are nonadherent to prescribed regimens. EULAR has commissioned a task force
Read Article